FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2534731438> ?p ?o ?g. }

• W2534731438 endingPage "1482" @default.
• W2534731438 startingPage "1482" @default.
• W2534731438 abstract "Abstract Introduction Recently there have been some reports of Peripheral Arterial Occlusive Disease (PAOD) in chronic myeloid leukemia (CML) patients treated with second generation Tyrosine Kinase inhibitor (TKI) nilotinib. PAOD is mainly caused by atherosclerosis, which is a multifactorial disease of the vessels involving lipid accumulation, thrombogenic components, cell death and inflammatory responses in the arterial wall. With the intent to elucidate a potential correlation between TKIs treatment and mechanisms underlining PAOD or other atherotrombotic events, we investigated a previously described (and confirmed in different settings) genetic and biochemical trait associated with vascular events, in a series of CML patients treated in with TKIs. Patients and Methods Seventy-five CML patients referring to three Italian Hematology Centers (Siena, Pisa and Firenze), of which 39 treated with imatinib and 36 with nilotinib (median treatment time 10 years, range 3-13ys and 3 years, range 2-6ys, respectively), all in complete cytogenetic response and with various degree of molecular response, entered the study. During a routine follow-up visit the patients were evaluated for: classical risk factors (Diabetes Mellitus, Dyslipidemia, Arterial Hypertension, Body Mass Index, Cigarette Smoking, Familiarity); sCD40L level and Endogenous Thrombin Potential (ETP) as markers of platelets and coagulation activation; oxidized LDL (oxLDL) level as early stage atherogenesis promoter; IL6, IL10, TNFα cytokines network as indicator of pro/anti-inflammatory balance; 3'UTR polymorphism of OLR1, encoding for the oxidized LDL receptor 1 (LOX-1), as independent genetic predisposition for atherotrombotic events. In addition the patients were screened for PAOD a/o other atherotrombotic episodes. Results The distribution of classical risk factors was homogeneous in the two groups of patients. On the contrary we noted significant differences in several biochemical parameters evaluated (Table 1). Evaluation of events (i.e. PAOD, Acute Coronary Syndrome and Cerebral Ischemia) showed a statistically significant difference in the two groups with 9/36 (25%) atherotrombotic events occurring in the nilotinib group and 3/39 (7.6%) events occurring in the imatinib group (p=0.019). Multivariate analysis showed that the most strictly related factors to the increased risk of events in this series of CML patients were: nilotinib treatment, oxLDL level (O.R.3.8 95% C.I. 1.8-6.9, p< 0.001, β 1.61), IL10 level (O.R.3.3 95% C.I. 1.9-5.1, p< 0.001, β 1.55) and the presence of an intermediate or high risk OLR1 variant allele (O.R.3.1 C.I. 1.6-4.8, p< 0.001, β 1.59). Discussion These preliminary data suggest that an unbalance of pro/anti-inflammatory cytokines network observed in nilotinib treated patients, together with genetic pro-atherothrombotic predisposition conferred by LOX-1, may have a role in the increased incidence of vascular events. The pro-inflammatory condition could be responsible of the pro-atherotrombotic activation, mainly by enhanced lipid peroxidation, as confirmed by altered sCD40L, ETP and oxLDL levels, despite the use of anti-atherothrombotic drugs. The link between pro-inflammatory stimuli and lipid peroxidation is a well established trigger of accelerated atherogenesis in the general population. As such, in a condition of potential increased lipid peroxidation as described in carriers of detrimental SNPs of LOX-1, the enhanced inflammatory milieu observed during nilotinib treatment could be an additional factor of accelerate atherothrombosis. Further studies are needed to both elucidate the mechanism underlining nilotinib-induced pro-inflammatory status and confirm LOX-1 mutations as a useful genetic tool to identify nilotinib-treated patients at potential increased atherothrombotic risk. Disclosures: Galimberti: Novartis and Bristol Mayer Squibb: Honoraria. Gozzini:Novartis and Bristol Mayer Squibb: Honoraria. Baratè:Novartis and Bristol Mayer Squibb: Honoraria. Scappini:Novartis and Bristol Mayer Squibb: Honoraria. Bosi:Novartis and Bristol Mayer Squibb: Honoraria. Petrini:Novartis and Bristol Mayer Squibb: Honoraria. Bocchia:Novartis and Bristol Mayer Squibb: Honoraria." @default.
• W2534731438 created "2016-10-28" @default.
• W2534731438 creator A5001285087 @default.
• W2534731438 creator A5002237220 @default.
• W2534731438 creator A5006110055 @default.
• W2534731438 creator A5011078993 @default.
• W2534731438 creator A5023419812 @default.
• W2534731438 creator A5030706737 @default.
• W2534731438 creator A5031078901 @default.
• W2534731438 creator A5032479923 @default.
• W2534731438 creator A5032968890 @default.
• W2534731438 creator A5039222522 @default.
• W2534731438 creator A5039833411 @default.
• W2534731438 creator A5055619912 @default.
• W2534731438 creator A5063459060 @default.
• W2534731438 creator A5071791178 @default.
• W2534731438 creator A5072006834 @default.
• W2534731438 creator A5077344066 @default.
• W2534731438 date "2013-11-15" @default.
• W2534731438 modified "2023-10-18" @default.
• W2534731438 title "Atherothrombotic Risk and TKIs Treatment In Chronic Myeloid Leukemia Patients: A Role For Genetic Predisposition and Pro-Inflammatory/Pro-Oxidative Status?" @default.
• W2534731438 doi "https://doi.org/10.1182/blood.v122.21.1482.1482" @default.
• W2534731438 hasPublicationYear "2013" @default.
• W2534731438 type Work @default.
• W2534731438 sameAs 2534731438 @default.
• W2534731438 citedByCount "6" @default.
• W2534731438 countsByYear W25347314382015 @default.
• W2534731438 countsByYear W25347314382016 @default.
• W2534731438 countsByYear W25347314382023 @default.
• W2534731438 crossrefType "journal-article" @default.
• W2534731438 hasAuthorship W2534731438A5001285087 @default.
• W2534731438 hasAuthorship W2534731438A5002237220 @default.
• W2534731438 hasAuthorship W2534731438A5006110055 @default.
• W2534731438 hasAuthorship W2534731438A5011078993 @default.
• W2534731438 hasAuthorship W2534731438A5023419812 @default.
• W2534731438 hasAuthorship W2534731438A5030706737 @default.
• W2534731438 hasAuthorship W2534731438A5031078901 @default.
• W2534731438 hasAuthorship W2534731438A5032479923 @default.
• W2534731438 hasAuthorship W2534731438A5032968890 @default.
• W2534731438 hasAuthorship W2534731438A5039222522 @default.
• W2534731438 hasAuthorship W2534731438A5039833411 @default.
• W2534731438 hasAuthorship W2534731438A5055619912 @default.
• W2534731438 hasAuthorship W2534731438A5063459060 @default.
• W2534731438 hasAuthorship W2534731438A5071791178 @default.
• W2534731438 hasAuthorship W2534731438A5072006834 @default.
• W2534731438 hasAuthorship W2534731438A5077344066 @default.
• W2534731438 hasConcept C126322002 @default.
• W2534731438 hasConcept C201267052 @default.
• W2534731438 hasConcept C203014093 @default.
• W2534731438 hasConcept C2777292125 @default.
• W2534731438 hasConcept C2777413986 @default.
• W2534731438 hasConcept C2777583451 @default.
• W2534731438 hasConcept C2778729363 @default.
• W2534731438 hasConcept C2779134260 @default.
• W2534731438 hasConcept C3019892230 @default.
• W2534731438 hasConcept C67636389 @default.
• W2534731438 hasConcept C71924100 @default.
• W2534731438 hasConcept C89560881 @default.
• W2534731438 hasConcept C90924648 @default.
• W2534731438 hasConceptScore W2534731438C126322002 @default.
• W2534731438 hasConceptScore W2534731438C201267052 @default.
• W2534731438 hasConceptScore W2534731438C203014093 @default.
• W2534731438 hasConceptScore W2534731438C2777292125 @default.
• W2534731438 hasConceptScore W2534731438C2777413986 @default.
• W2534731438 hasConceptScore W2534731438C2777583451 @default.
• W2534731438 hasConceptScore W2534731438C2778729363 @default.
• W2534731438 hasConceptScore W2534731438C2779134260 @default.
• W2534731438 hasConceptScore W2534731438C3019892230 @default.
• W2534731438 hasConceptScore W2534731438C67636389 @default.
• W2534731438 hasConceptScore W2534731438C71924100 @default.
• W2534731438 hasConceptScore W2534731438C89560881 @default.
• W2534731438 hasConceptScore W2534731438C90924648 @default.
• W2534731438 hasIssue "21" @default.
• W2534731438 hasLocation W25347314381 @default.
• W2534731438 hasOpenAccess W2534731438 @default.
• W2534731438 hasPrimaryLocation W25347314381 @default.
• W2534731438 hasRelatedWork W1510497893 @default.
• W2534731438 hasRelatedWork W2051726599 @default.
• W2534731438 hasRelatedWork W2073935113 @default.
• W2534731438 hasRelatedWork W2120868842 @default.
• W2534731438 hasRelatedWork W2420649402 @default.
• W2534731438 hasRelatedWork W2488200262 @default.
• W2534731438 hasRelatedWork W2534731438 @default.
• W2534731438 hasRelatedWork W4230849756 @default.
• W2534731438 hasRelatedWork W4245675997 @default.
• W2534731438 hasRelatedWork W54919303 @default.
• W2534731438 hasVolume "122" @default.
• W2534731438 isParatext "false" @default.
• W2534731438 isRetracted "false" @default.
• W2534731438 magId "2534731438" @default.
• W2534731438 workType "article" @default.